Eris Biotech

Executive Summary

Eris Biotech is a privately held biotechnology company headquartered in San Diego, founded in 2015, that focuses on developing novel small-molecule therapies to overcome immune evasion in cancer. Their lead program is a first-in-class, orally administered inhibitor targeting a key immune evasion pathway that is broadly applicable across multiple tumor types, not reliant on a specific protein target. This approach has the potential to address a large patient population by reactivating the immune system against cancer cells. The company has advanced its preclinical pipeline and is approaching clinical-stage development, aiming to file an Investigational New Drug (IND) application within the next year. The company's innovative strategy positions it as a compelling player in the immuno-oncology space, where there is high unmet need for oral therapies that can complement existing checkpoint inhibitors. Eris Biotech's platform could offer a differentiated mechanism that may overcome resistance to current immunotherapies. While the company remains private and has not disclosed significant financing rounds, its progress toward the clinic and the novelty of its approach suggest potential for value creation through clinical validation and strategic partnerships. Investors should monitor upcoming milestones, including regulatory submissions and early clinical data, which will be critical for assessing the therapeutic potential and commercial viability of its lead candidate.

Upcoming Catalysts (preview)

• Q3 2026IND submission for lead oral immune evasion inhibitor70% success
• H2 2026Preclinical proof-of-concept data presentation at a major oncology conference90% success
• 2027Strategic partnership or licensing deal for candidate development40% success